Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Incidents of deviations from protocol
研究概览
简要总结
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
详细描述
Unfractionated heparin is classified as a high-alert medication in the acute care setting.3 Therapeutic anticoagulation is a high priority for healthcare teams because the impacts of inadequate anticoagulation can lead to life threatening events such as a major bleed or thrombus formation and/or death.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy
排除标准
- •History of bleeding in the last 30 days
- •History of HIT
- •Use of systemic anticoagulants for another indication
- •Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)
结局指标
主要结局
Incidents of deviations from protocol
时间窗: 30 Days
Appropriate anticoagulation management will be measured using Percent time in therapeutic range based on aPTT levels
次要结局
未报告次要终点